درباره این اپیزود
What happens when you leave a wellness-focused longevity conference in Berlin and fly straight into one of the world's premier scientific aging research meetings?In this special recap from Day 1 of the 2026 American Aging Association (AGE) Annual Meeting, I sit down with Dr. Kevin White to discuss the biggest themes emerging from the conference and what they tell us about the current state of the longevity field.One theme stood out above all others: rapamycin and mTOR biology continue to dominate the scientific conversation around aging. From immune function and inflammation to ovarian aging, brain health, and metabolism, the evidence supporting mTOR as a central regulator of aging appears stronger than ever.We also discuss the growing disconnect between evidence-based aging science and the broader wellness industry. While scientific meetings like AGE focus on rigorous basic, translational, and clinical research, much of the public conversation around longevity is increasingly driven by influencers, untested interventions, and marketing hype.Other topics include:New research on rapamycin and immune resilienceWhy mTOR remains one of the most important pathways in aging biologyThe decline of the NAD/sirtuin narrative and where the field is heading nextMicroplastics and what the science actually says about riskGut microbiome research and healthy agingCircadian biology, sleep, and longevityThe importance of clinical trials in longevity medicineWhy scientists and clinicians need to work more closely togetherIf you're interested in separating evidence-based longevity science from hype, this conversation provides an inside look at what leading researchers are actually discussing today.
